Compounds > clarithromycin
Page last updated: 2024-08-25

clarithromycin and Pyelonephritis

clarithromycin has been researched along with Pyelonephritis in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's7 (77.78)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Furleta, VV; Nykula, TD1
Baba, S; Furuhata, M; Inoue, M; Iwamura, M1
Adamis, T; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Koussoulas, V; Laoutaris, G; Mouktaroudi, M; Perrea, D; Sabracos, L1
Antonopoulou, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kousoulas, V; Koutoukas, P; Panagou, C; Perrea, D; Sabracos, L1
Adamis, T; Baziaka, F; Giamarellos-Bourboulis, E; Giamarellou, H; Karayannacos, P; Koutoukas, P; Plachouras, D; Raftogiannis, M; Sabracos, L; Tsaganos, T1
Adamis, T; Antonopoulou, A; Giamarellos-Bourboulis, EJ; Giamarellou, H; Koutoukas, P; Panagou, C; Raftogiannis, M; Tsaganos, T; Tziortzioti, V1
Adamis, T; Antonopoulou, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Koutoukas, P; Raftogiannis, M; Sabracos, L; Tziortzioti, V1
Adamis, T; Baziaka, F; Chrisofos, M; Douzinas, EE; Giamarellos-Bourboulis, EJ; Giamarellou, H; Koutoukas, P; Raftogiannis, M; Sabracos, L; Tziortzioti, V1
Kees, F; Peters, F; Raasch, W; Sedlmayr, T1

Other Studies

9 other study(ies) available for clarithromycin and Pyelonephritis

ArticleYear
[Rationale for improved treatment of ulcerative disease complicated by chronic pyelonephritis].
    Likars'ka sprava, 2013, Issue:4

    Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Diet; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Kidney; Male; Middle Aged; Pyelonephritis; Rabeprazole; Risk Factors; Treatment Outcome; Ulcer

2013
Combined effect of clarithromycin and imipenem/cilastatin against urinary biofilm infection after pyeloplasty.
    International journal of urology : official journal of the Japanese Urological Association, 2003, Volume: 10, Issue:4

    Topics: Adult; Biofilms; Cilastatin; Clarithromycin; Drug Therapy, Combination; Humans; Imipenem; Kidney Calculi; Kidney Pelvis; Male; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Staphylococcal Infections; Staphylococcus epidermidis; Treatment Outcome; Ureteral Obstruction

2003
Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:1

    Topics: Acute Disease; Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Immunity; Lipopolysaccharides; Male; Malondialdehyde; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Sepsis; Survival Analysis; Tumor Necrosis Factor-alpha

2004
Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.
    International journal of antimicrobial agents, 2005, Volume: 25, Issue:2

    Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Inflammation; Lipopolysaccharides; Malondialdehyde; Pyelonephritis; Rabbits; Sepsis; Treatment Outcome; Tumor Necrosis Factor-alpha

2005
Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli.
    Scandinavian journal of infectious diseases, 2005, Volume: 37, Issue:1

    Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Caspase 3; Caspases; Clarithromycin; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Immunologic Factors; Male; Malondialdehyde; Pulmonary Edema; Pyelonephritis; Rabbits; Sepsis; Tumor Necrosis Factor-alpha

2005
Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
    BMC infectious diseases, 2006, Feb-21, Volume: 6

    Topics: Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Immunologic Factors; Kidney; Lipopolysaccharides; Liver; Lung; Male; Malondialdehyde; Monocytes; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Spleen; Tumor Necrosis Factor-alpha

2006
Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 57, Issue:5

    Topics: Acute Disease; Animals; Anti-Bacterial Agents; Caspase 3; Caspases; Clarithromycin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Immunologic Factors; Injections, Intravenous; Klebsiella pneumoniae; Male; Monocytes; Pyelonephritis; Rabbits; Tumor Necrosis Factor-alpha

2006
Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Humans; Immunologic Factors; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Sepsis

2008
[Clarithromycin, a new macrolide antibiotic. Effectiveness in puerperal infections and pharmacokinetics in breast milk].
    Geburtshilfe und Frauenheilkunde, 1993, Volume: 53, Issue:7

    Topics: Administration, Oral; Adult; Clarithromycin; Endometritis; Episiotomy; Female; Humans; Milk, Human; Puerperal Infection; Pyelonephritis; Surgical Wound Infection

1993